EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP

BACKGROUND: Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). The landscape of somatic mutations in DLBCL revealed that inactivation of EP300 plays an important role in lymphomagen...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Cell Int
Main Authors: Li, Jiao, Ding, Ning, Wang, Xiaogan, Mi, Lan, Ping, Lingyan, Jin, Xuan, Liu, Yalu, Ying, Zhitao, Xie, Yan, Liu, Weiping, Song, Yuqin, Zhu, Jun
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Primary Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5513029/
https://ncbi.nlm.nih.gov/pubmed/28725161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-017-0439-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares